---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-094758"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:14:56.771838+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials

## Summary
- Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.
- Net proceeds plus existing cash expected to fund operations into 2028, excluding full AXPAXLI commercial launch costs.
- Funds to support AXPAXLI open-label extension in wet AMD, Phase 3 trials in NPDR, and manufacturing scale-up.
- Offering expected to close Oct 1, 2025; BofA Securities, TD Cowen, Piper Sandler & Co. acting as joint book-runners.

## SEC filing metadata
- accession: 0001104659-25-094758
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/0001104659-25-094758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/tm2527344d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-094758
- JSON: https://secwatch.observer/filing/0001104659-25-094758.json
- Plain text: https://secwatch.observer/filing/0001104659-25-094758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.